Form 4: Pacira BioSciences Director Marcelo Bigal Receives Significant Equity Grant

Pacira BioSciences, Inc. Director Marcelo Bigal was granted 6,163 restricted stock units and 11,279 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Marcelo Bigal, a Director at Pacira BioSciences, Inc. (PCRX), reported the acquisition of equity securities.
• On June 11, 2025, Mr. Bigal was granted 6,163 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per unit.
• Each RSU represents the contingent right to receive one share of the issuer's common stock.
• These RSUs are scheduled to vest on June 11, 2026, provided Mr. Bigal remains in continuous service with Pacira BioSciences.
• Following this transaction, Mr. Bigal beneficially owns 16,305 shares of Common Stock.
• Additionally, on June 11, 2025, Mr. Bigal was granted 11,279 Stock Options (Right to Buy) at an exercise price of $24.34 per share.
• These stock options were acquired at a price of $0 and are scheduled to vest and become exercisable on June 11, 2026, contingent on continuous service.
• The stock options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Bigal beneficially owns 11,279 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects a standard and beneficial practice of aligning director interests with shareholder value through equity compensation. It's a routine transaction that strengthens governance and incentivizes long-term commitment.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests directly with the long-term performance and shareholder value of Pacira BioSciences, Inc.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's growth and success.
• The acquisition of 6,163 restricted stock units and 11,279 stock options represents a significant equity stake for the director.

Negatives

• The restricted stock units and stock options are subject to a one-year vesting period, meaning the director does not immediately have full ownership or exercisability.
• The value of the equity compensation is contingent on the future stock price performance of Pacira BioSciences, Inc.

Risks

• The restricted stock units and stock options are subject to forfeiture if the reporting person does not remain in continuous service with the issuer through the vesting date of June 11, 2026.
• The value realized from the stock options is dependent on the stock price exceeding the exercise price of $24.34 at the time of exercise.

Future Outlook

The vesting schedules for both the restricted stock units and stock options, set for June 11, 2026, indicate an expectation of continued service from Director Marcelo Bigal. The stock options' expiration in 2035 provides a long-term incentive for the director to contribute to the company's sustained growth and share price appreciation.

Industry Context

The grant of equity compensation, including restricted stock units and stock options, is a common and widely accepted practice in the biotechnology and pharmaceutical industries. It serves to attract, retain, and incentivize key personnel, including directors, by aligning their financial success with the company's performance and shareholder returns. This practice is consistent with typical compensation structures for directors in publicly traded life sciences companies.

Comparison to Industry Standards

• Equity compensation for directors, comprising a mix of restricted stock units and stock options, is a standard component of remuneration packages across the biotechnology and pharmaceutical sectors.
• While specific grant sizes vary based on company size, performance, and individual roles, the structure observed for Director Bigal is consistent with common industry practices aimed at fostering long-term alignment between directors and shareholder interests.
• Companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) frequently utilize similar equity-based incentives for their non-employee directors, often with vesting periods tied to continued board service.

Stakeholder Impact

• Shareholders: The grant of equity compensation aligns the director's interests with those of the shareholders, potentially leading to better long-term decision-making aimed at increasing shareholder value. However, it also represents a potential future dilution of existing shares upon vesting and exercise.
• Director (Marcelo Bigal): This transaction provides significant equity-based compensation, incentivizing his continued service and performance as a director.

Next Steps

• The restricted stock units and stock options are scheduled to vest on June 11, 2026, contingent on Marcelo Bigal's continuous service with Pacira BioSciences, Inc.
• Upon vesting, the restricted stock units will convert into shares of common stock, and the stock options will become exercisable.

Key Dates

Keywords

Pacira BioSciences, PCRX, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Corporate Governance, Executive Compensation